FK506 protects neurons following peripheral nerve injury via immunosuppression.
In this study, we have evaluated neuroprotective effect of an immunosuppressant immunophilin ligand, FK506, in the sciatic nerve injury model in rats. FK506 was injected to the sciatic nerve transected 3-month-old female Wistar rats (2 mg/kg/day starting 1 day prior to sciatic nerve injury up to 7 day post operation). Equal number of sciatic nerve transected animals served as injured untreated controls. The contralateral side served as respective control. L4-L5 region of the spinal cord was removed on day 1, 3, 7, 14, 21, and 28, post operation and then processed for cryo-sectioning and paraffin sectioning. The cryocut sections were used for immunohistochemistry for localizing all microglia (using anti-Iba-1) and MHC-II expressing microglia (with OX-6). The physical dissector method was applied on Nissl stained paraffin sections for absolute motor neuron counting in the L4-L5 region of spinal cord. FK506 treated animals presented 88.7% neuronal survival while the injured alone had 79.12%, which is significantly less than the treated animals. FK506 caused early proliferation of microglia at 1 and 3 days post operation. FK506 also significantly restricted transformation of these cells in to phagocytes. Colocalization of activated microglia by anti-Iba-1 and OX-6 antibodies, confirms that the MHC-II expressing cells in injured spinal cord are none other than microglial cells and MHC-II expressing cells are significantly less in treated as compared to untreated injured animals. We propose that immunosuppression is one of the main mechanisms by which FK506 protects the central neurons following peripheral injury.
Saxena
Kapil
K
School of Studies in Neuroscience, Jiwaji University, Gwalior, Madhya Pradesh, 474011, India. kapilsaxena@gmail.com
Patro
Nisha
N
Patro
Ishan
I
D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival; D019610:Cytoprotection / Q000187:drug effects / Q000276:immunology; D004353:Drug Evaluation, Preclinical; D005260:Female; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology; D017628:Microglia / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology; D010523:Peripheral Nervous System Diseases / Q000276:immunology*; D010641:Phenotype; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000276:immunology / Q000293:injuries*; D016559:Tacrolimus / Q000494:pharmacology*
D007166:Immunosuppressive Agents; D018696:Neuroprotective Agents; D016559:Tacrolimus